ATC Group: N05AX12 Aripiprazole

Anatomical Therapeutic Chemical Classification System

Hierarchical position in ATC classification

Level
Code
Title
1
Nervous system
2
Psycholeptics
3
Antipsychotics
4
Other antipsychotics
5
N05AX12
Aripiprazole

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route
Amount
ORAL - Oral
15 mg
PAREN - Parenteral
15 mg
PAREN - Parenteral (depot)
13.2 mg

Active ingredients

Active Ingredient
Description

It has been proposed that aripiprazole’s efficacy in schizophrenia and Bipolar I Disorder is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism of serotonin 5-HT2A receptors.

Medicines in this ATC group

Drug
Countries

Italy Tunisia

Spain

Australia Austria Canada Cyprus Estonia ...

South Africa

Australia

Brazil

Poland

South Africa

Estonia Lithuania

South Africa

Poland

Estonia Lithuania Poland

Hong Kong

Estonia Lithuania

South Africa

Ecuador Spain

Brazil

Cyprus Germany

Ecuador

Germany United Kingdom

Hong Kong Poland

Brazil

Cyprus

Brazil

Brazil

Ecuador

Brazil

Estonia Lithuania

South Africa

Brazil

Brazil

South Africa

South Africa

Cyprus Estonia Lithuania Spain

Related product monographs

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)